In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed the day trading at $19.23 down -1.54% from the previous closing price of $19.53. In other words, the price has decreased by -$1.54 from its previous closing price. On the day, 1.13 million shares were traded.
Ratios:
For a better understanding of ARWR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.09 and its Current Ratio is at 6.09. In the meantime, Its Debt-to-Equity ratio is 16.58 whereas as Long-Term Debt/Eq ratio is at 16.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 23 ’25 when OLUKOTUN ADEOYE Y sold 959 shares for $21.00 per share. The transaction valued at 20,139 led to the insider holds 35,781 shares of the business.
OLUKOTUN ADEOYE Y bought 959 shares of ARWR for $20,108 on Jan 23 ’25. On Jan 06 ’25, another insider, Hamilton James C, who serves as the Chief Discovery/Trans Medicine of the company, sold 32,729 shares for $19.82 each. As a result, the insider received 648,824 and left with 272,122 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 969.95 while its Price-to-Book (P/B) ratio in mrq is 45.92.
Stock Price History:
Over the past 52 weeks, ARWR has reached a high of $36.72, while it has fallen to a 52-week low of $17.05. The 50-Day Moving Average of the stock is -3.12%, while the 200-Day Moving Average is calculated to be -14.04%.
Shares Statistics:
A total of 125.57M shares are outstanding, with a floating share count of 116.97M. Insiders hold about 7.24% of the company’s shares, while institutions hold 77.04% stake in the company.
Earnings Estimates
The stock of Arrowhead Pharmaceuticals Inc (ARWR) is currently being evaluated by 12.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$1.02, with high estimates of -$0.29 and low estimates of -$1.35.
Analysts are recommending an EPS of between $1.53 and -$5.52 for the fiscal current year, implying an average EPS of -$3.6. EPS for the following year is -$3.94, with 11.0 analysts recommending between -$0.92 and -$5.42.
Revenue Estimates
A total of 16 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $906.5M, while the lowest revenue estimate was $2.5M, resulting in an average revenue estimate of $291.34M. In the same quarter a year ago, actual revenue was $3.55MBased on 14 analysts’ estimates, the company’s revenue will be $218.69M in the next fiscal year. The high estimate is $565.7M and the low estimate is $38.75M.
